Опубликована: Янв. 1, 2024
Язык: Английский
European Urology Oncology, Год журнала: 2024, Номер 7(5), С. 1105 - 1112
Опубликована: Март 22, 2024
Язык: Английский
Процитировано
13
Current Oncology Reports, Год журнала: 2025, Номер unknown
Опубликована: Фев. 12, 2025
Язык: Английский
Процитировано
1
Cancer Cell International, Год журнала: 2025, Номер 25(1)
Опубликована: Март 1, 2025
At present, there is no effective prognostic indicator for muscle invasive bladder cancer (MIBC). A liquid biopsy method, plasma circulating tumor DNA (ctDNA) detection, was evaluated use in predicting the prognosis of different cancers. This study aims to assess value ctDNA state muscle-invasive patients. We comprehensively searched three public databases (PubMed, EMBASE, and Cochrane Library) December 2023 according Preferred Reporting Items Systematic Review Meta-analysis (PRISMA) statement. Studies investigating outcome indicators patients with MIBC were included our analysis. The hazard ratios (HRs) 95% confidence intervals (CIs) extracted evaluate association between MIBC. Eleven studies 1,170 diagnosed cancer, comprising a total four retrospective cohort eight prospective studies, meta-analysis, one which had two cohorts. analysis revealed that positive associated poor overall survival (OS), progression-free (PFS), recurrence-free (RFS) (HR = 4.51, CI: 2.64–7.69, P < 0.001; HR 4.50, 2.77–7.30, 6.56, 4.18–10.30, 0.001), significant effects both pre- post-treatment. In addition, longitudinal proved be monitoring receiving treatments 0.24, 0.14–0.41, 0.001). OS, PFS, RFS Meanwhile, clearance improved These findings suggest predictive MIBC, can used monitor recurrence guide treatment. Thus, level detection shows potential treatment
Язык: Английский
Процитировано
1
Indian Journal of Urology, Год журнала: 2025, Номер 41(2), С. 98 - 103
Опубликована: Апрель 1, 2025
ABSTRACT MicroRNAs, small noncoding RNA molecules, are critical in modulating gene expression and contribute substantially to the initiation progression of urinary bladder cancer (UBCa), a major malignancy affecting people globally. UBCa is known for its high recurrence rates significant heterogeneity. The stability miRNAs body fluids such as urine blood excellent potential noninvasive markers early detection, monitoring treatment progress, predicting outcomes patients with UBCa. In addition, could also improve effectiveness immunotherapy support development personalized strategies. Despite their potential, challenges variability shortcomings delivery systems must be carefully addressed. This strength, weakness, opportunity, threat (SWOT) analysis highlights crucial role explores advancing precision oncology.
Язык: Английский
Процитировано
1
Nature Medicine, Год журнала: 2024, Номер 30(9), С. 2508 - 2516
Опубликована: Июнь 1, 2024
Abstract Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with and without chemotherapy was compared alone patients cancer. The study did not meet prespecified efficacy thresholds for statistical significance. To identify biomarkers of response, we retrospectively evaluated association pre- posttreatment ctDNA clinical outcomes subset who received ( n = 130) or KEYNOTE-361. Baseline associated best overall response (BOR; P 0.009), progression-free survival < 0.001) (OS; (all; > 0.05). Chemotherapy induced larger decreases from baseline to treatment cycle 2 than pembrolizumab; however, change 87) more BOR 4.39 × 10 −5 ) OS 7.07 102; BOR: 1.01 −4 ; OS: 0.018). Tumor tissue-informed versions metrics were most show statistically significant independent value explaining beyond radiographic by RECIST v.1.1 when jointly modeled (pembrolizumab 0.364; 0.823). These results suggest distinct patterns early changes immunotherapy differences their long-term outcomes, which provide preliminary insights into liquid biopsies monitoring Clinical trial registration: NCT02853305 .
Язык: Английский
Процитировано
8
Oncotarget, Год журнала: 2024, Номер 15(1), С. 200 - 218
Опубликована: Март 14, 2024
// Josette Northcott 1 , Gabor Bartha Jason Harris Conan Li Fabio C.P. Navarro Rachel Marty Pyke Manqing Hong Qi Zhang Shuyuan Ma Tina X. Chen Janet Lai Nitin Udar Juan-Sebastian Saldivar Erin Ayash Joshua Anderson Jiang Tiange Cui Tu Le Ruthie Chow Randy Jerel Velasco Chris Mallo Rose Santiago Robert C. Bruce Laurie J. Goodman Yi Dan Norton Richard O. * and John M. Lyle Personalis, Inc., Fremont, CA 94555, USA Co-last authors Correspondence to: Lyle, email: [email protected] Keywords: circulating tumor DNA; whole genome sequencing; molecular residual disease; tumor-informed assay; analytical validation Received: December 11, 2023 Accepted: February 12, 2024 Published: March 14, Copyright: © et al. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, reproduction in any medium, provided original author source are credited. ABSTRACT We describe NeXT Personal ® ultra-sensitive, DNA (ctDNA) assay for detecting disease, monitoring therapy response, recurrence patients diagnosed with solid cancers. uses sequencing matched normal samples combined advanced analytics to accurately identify up ~1,800 somatic variants specific patient's tumor. A personalized panel created, targeting these then used sequence cell-free extracted from patient plasma ultra-sensitive detection ctDNA. The based on panels designed two cell lines, 123 across nine cancer types. Analytical measurements demonstrated a threshold 1.67 parts per million (PPM) limit at 95% (LOD 95 ) 3.45 PPM. showed linearity over range 0.8 300,000 PPM (Pearson correlation coefficient = 0.9998). Precision varied variation 12.8% 3.6% 25 25,000 targets 99.9% specificity, this study measuring 100% specificity silico methods giving us confidence interval 99.92 100%. In summary, demonstrates as highly quantitative robust ctDNA that can be detect monitor treatment patients.
Язык: Английский
Процитировано
7
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(23), С. 16578 - 16578
Опубликована: Ноя. 21, 2023
Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be feasible strategy monitor disease progression therapeutic response in muscle-invasive bladder (MIBC) patients after radical cystectomy (RC). Forty-two MIBC who underwent RC were prospectively included. Blood samples from these collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T ATM c.1236-2A>T) analyzed the patients' plasma by droplet digital PCR determine their status. During median of 21 months, 24% progressed six months. status was identified before 4 12 months later (HR 6.774, HR 3.673, 30.865, respectively; p < 0.05). Lastly, dynamic changes between baseline four significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal analysis using approach is potential tool RC. The implementation this clinical setting could improve management outcomes.
Язык: Английский
Процитировано
11
European Urology Oncology, Год журнала: 2024, Номер unknown
Опубликована: Июль 1, 2024
Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers urgently needed to refine prognostication and selection appropriate perioperative systemic therapies. Our aim was evaluate the prognostic predictive value tumor-informed circulating tumor DNA (ctDNA) results in a multicenter cohort who underwent RC.
Язык: Английский
Процитировано
4
European Urology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(5), С. 728 - 728
Опубликована: Фев. 21, 2025
In recent decades, serum tumor markers (STMs) have emerged as valuable adjuncts in early cancer detection and post-treatment surveillance. STMs are inexpensive, minimally invasive, readily accessible tools that can be used to diagnose cancers, monitor patients’ responses treatment, even detect recurrence without imposing additional burdens on patients. Emerging evidence has demonstrated the reliability of prognostication bladder (BC). However, their potential role extends beyond prognostication. This review intends provide a multidimensional picture STM applications muscle-invasive (MIBC). addition, we supplement this with real-life clinical experiences from our institution further illustrate feasibility MIBC.
Язык: Английский
Процитировано
0